Boston Scientific Investors Seek Lead Plaintiff Role in Class Action Lawsuit

Investors with substantial losses have until May 4, 2026 to seek appointment as lead plaintiff in the case against Boston Scientific Corporation.

Mar. 22, 2026 at 10:34pm

Got story updates? Submit your updates here. ›

The law firm of Robbins Geller Rudman & Dowd LLP has announced that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026 have until May 4, 2026 to seek appointment as lead plaintiff in a class action lawsuit against the company. The lawsuit alleges that Boston Scientific and certain of its top executives made false and/or misleading statements and/or failed to disclose information about the company's projected revenue outlook and anticipated growth, as well as new competition that was limiting its market share and growth potential.

Why it matters

This class action lawsuit represents an opportunity for Boston Scientific investors who suffered substantial losses during the class period to potentially recoup those losses and hold the company accountable for any alleged wrongdoing. The outcome of the case could have significant financial implications for both the investors and the company.

The details

The lawsuit, captioned Troike v. Boston Scientific Corporation, No. 26-cv-40075 (D. Mass.), alleges that Boston Scientific and its executives created a false impression about the company's projected revenue and growth, while minimizing risks from seasonality and macroeconomic fluctuations. The lawsuit further alleges that Boston Scientific's ambition to grow its share in the electrophysiology market at 2x the market rate had fallen short due to new competition that was sapping the company's U.S. market share and limiting its growth potential.

  • The class period for the lawsuit is from July 23, 2025 to February 3, 2026, both dates inclusive.
  • Investors have until May 4, 2026 to seek appointment as lead plaintiff in the class action lawsuit.

The players

Robbins Geller Rudman & Dowd LLP

A law firm representing investors in securities fraud and shareholder rights litigation, and the firm that has announced the class action lawsuit against Boston Scientific Corporation.

Boston Scientific Corporation

A medical device company that develops, manufactures, and markets products for various interventional medical specialties worldwide.

Got photos? Submit your photos here. ›

What they’re saying

“If you suffered substantial losses and wish to serve as lead plaintiff of the Boston Scientific class action lawsuit, please provide your information here:”

— J.C. Sanchez, Attorney, Robbins Geller

“You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.”

— J.C. Sanchez, Attorney, Robbins Geller

What’s next

Investors have until May 4, 2026 to seek appointment as lead plaintiff in the class action lawsuit against Boston Scientific Corporation.

The takeaway

This class action lawsuit represents an opportunity for Boston Scientific investors who suffered substantial losses to potentially recoup those losses and hold the company accountable for any alleged wrongdoing. The outcome of the case could have significant financial implications for both the investors and the company.